Dynomics
San Mateo
About Dynomics
We target therapeutics to human heart function, taking a precision approach to drug development and capturing the adult heart clinical phenotype. This is powered by our scalable, authentic and predictive discovery engine - HeartDyno. HeartDyno is built with engineered human cardiac organoids, scalably deployed to drive a multi-omics data-driven approach. It rapidly uncovers novel therapeutic targets and candidates that offer superior efficacy and safety profiles in humans. Dynomics’ approach is validated through collaboration with top pharmaceutical companies, top-tier scientific publications, and we are progressing assets targeting heart failure, affecting 4% of the US population and where current treatments provide a 50% 5-year survival rate.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $500.0K
- Funding stage: Seed
- Last round: Pre-Seed (Oct 2020)
- Website: dynomics.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/dynomics-104745 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.